Population-based estimates of post-acute sequelae of SARS-CoV-2 infection (PASC) prevalence and characteristics

Jana L. Hirschtick\textsuperscript{a}, Andrea R. Titus\textsuperscript{a}, Elizabeth Slocum\textsuperscript{a}, Laura E. Power\textsuperscript{a}, Robert E. Hirschtick\textsuperscript{b}, Michael R. Elliott\textsuperscript{c,d}, Patricia McKane\textsuperscript{e}, Nancy L. Fleischer\textsuperscript{a}

\textsuperscript{a}Department of Epidemiology, University of Michigan School of Public Health, 1415 Washington Heights, Ann Arbor, MI 48109, USA

\textsuperscript{b}Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St. Clair, Suite 2330, Chicago, IL 60611, USA

\textsuperscript{c}Department of Biostatistics, University of Michigan School of Public Health, 1415 Washington Heights, Ann Arbor, MI 48109, USA

\textsuperscript{d}Survey Research Center, Institute for Social Research, 426 Thompson Street, Ann Arbor, MI 48109, USA

\textsuperscript{e}Lifecourse Epidemiology and Genomics Division, Michigan Department of Health and Human Services, 333 S. Grand Ave., Lansing, MI 48909, USA

Corresponding author
Jana Hirschtick, PhD, MPH
1415 Washington Heights
Ann Arbor, MI 48109
janahirs@umich.edu
734-764-3644 (phone)
734-763-5706 (fax)

Alternate author
Nancy Fleischer, PhD, MPH
1415 Washington Heights
Ann Arbor, MI 48109
nancyfl@umich.edu
734-764-3644 (phone)
734-763-5706 (fax)

Summary: In this population-based probability sample of symptomatic COVID-19 cases (n=593), 52.5% had persistent symptoms 30 days post-onset, with 35.0% symptomatic 60 days post-onset. Individuals with very severe acute illness had statistically significantly higher prevalence of persistent symptoms at 60 days.
Abstract

Background: Emerging evidence suggests many people have persistent symptoms after acute COVID-19 illness. Our objective was to estimate the prevalence and correlates of post-acute sequelae of SARS-CoV-2 infection (PASC).

Methods: We employed a population-based probability survey of adults with COVID-19 in Michigan. Living non-institutionalized adults aged 18+ in the Michigan Disease Surveillance System with COVID-19 onset through mid-April 2020 were eligible for selection (n=28,000). Among 2,000 selected, 629 completed the survey between June - December 2020. We estimated PASC prevalence, defined as persistent symptoms 30+ (30-day COVID-19) or 60+ days (60-day COVID-19) post COVID-19 onset, overall and by sociodemographic and clinical factors, including self-reported symptom severity and hospitalization status. We used modified Poisson regression to produce adjusted prevalence ratios (aPR) for potential risk factors.

Results: The analytic sample (n=593) was predominantly female (56.1%), aged 45 and older (68.2%), and Non-Hispanic White (46.3%) or Black (34.8%). 30- and 60-day COVID-19 were highly prevalent (52.5% and 35.0%), even among non-hospitalized respondents (43.7% and 26.9%) and respondents reporting mild symptoms (29.2% and 24.5%). Respondents reporting very severe (vs. mild) symptoms had 2.25 times higher prevalence of 30-day COVID-19 ([aPR] 2.25, 95% CI 1.46-3.46) and 1.71 times higher prevalence of 60-day COVID-19 (aPR 1.71, 95% CI 1.02-2.88). Hospitalized (vs. non-hospitalized) respondents had about 40% higher prevalence of both 30-day (aPR 1.37, 95% CI 1.12-1.69) and 60-day COVID-19 (aPR 1.40, 95% CI 1.02-1.93).

Conclusions: PASC is highly prevalent among cases reporting severe initial symptoms, and, to a lesser extent, cases reporting mild and moderate symptoms.

Keywords: COVID-19, PASC, probability survey
**Introduction**

The United States continues to be heavily impacted by the COVID-19 pandemic, with over 29 million confirmed cases and 527,000 deaths as of March 13, 2021 [1]. Emerging evidence indicates that a subset of people with COVID-19, commonly referred to as “long-haulers,” experience persistent symptoms for weeks or months after their COVID-19 diagnosis [2-13]. Given the disproportionate number of cases in the US, and a global case tally over 119 million [14], long-term COVID-19 health effects for even a fraction of cases will have significant public health and economic implications.

We currently know very little about this prolonged course of COVID-19, also known as post-acute sequelae of SARS-CoV-2 infection (PASC). It appears to commonly manifest with symptoms of extreme fatigue [3, 6-11, 13], shortness of breath [3, 5, 7, 8, 10], persistent loss of taste or smell [5, 10, 13], and cognitive dysfunction [5-7]. Due to the lack of a clear definition [15] and very few population-based studies, prevalence estimates vary greatly, ranging from 13% of cases with persistent symptoms at least 4 weeks post diagnosis [11] to 87% of hospitalized patients with symptoms an average of 60 days post symptom onset [3]. While some studies have shown an association between increasing age [11-13] or female sex [11] and PASC, others have not [2, 5]. Similarly, several studies report no association between comorbidities and risk of PASC [2, 5, 13], while others found increased risk among people with asthma [11], obesity [12], or a pre-existing psychiatric condition [12]. Despite this lack of clarity, there is emerging evidence that severity of acute illness, measured by number of symptoms [5, 11, 13], severity score [9], or hospitalization [11], may increase the risk of PASC.

The existing literature base is narrow and includes very few population-based studies needed to provide accurate prevalence estimates. Furthermore, we do not have a clear understanding of who is at increased risk of experiencing PASC. Our objectives for this study are to 1) provide PASC prevalence estimates using a population-based sample of diagnosed COVID-19 cases in Michigan, and 2) assess demographic and clinical correlates of PASC.

**Methods**

The University of Michigan institutional review board deemed this study exempt due to the use of secondary de-identified data.

**MI CReSS Sample**

The Michigan COVID-19 Recovery Surveillance Study (MI CReSS) is a population-based study of adults 18 and older with a PCR-confirmed SARS-CoV-2 test in the Michigan Disease Surveillance System (MDSS). All non-institutionalized adults with a valid phone number and zip code or county in MDSS who were alive at the time the survey sample was drawn were eligible for selection (n=28,000). We drew a stratified, random sample of 2,000 adults with COVID-19 onset on or before April 15, 2020. COVID-19 onset was determined by self-reported symptom onset date, obtained during public health case investigation, when available (87% of respondents), followed by positive SARS-CoV-2 test date (12%), or date of referral to the Michigan Department of Health and Human Services (MDHHS, 1%).

Sampling strata included 13 geographic areas in Michigan: six emergency preparedness regions [16] each consisting of multiple counties, six counties (Macomb; Oakland; St. Clair; Monroe; Washtenaw; Wayne, excluding Detroit) and one city (Detroit) in southeast Michigan, the epicenter of the initial outbreak in Michigan. We first drew a “base” sample of 70 from each stratum except for one with fewer than 70 cases at the time of sampling. We then drew the remainder of the sample from each stratum proportional to the total number of cases in the dataset. Sampling weights were constructed using generalized regression estimators.
so that the weighted distribution of the sample matched the age and sex distribution by geographic region of the sampling frame. These weights correct for over- and undersampling by geographic region and differential non-response by age and sex.

We sent selected cases a recruitment letter in mid-June 2020, inviting them to complete a survey online or via telephone in English, Spanish, or Arabic. Of the 2,000 adults selected, 79 were subsequently excluded due to death (n=12); cognitive impairment (n=41); inability to complete the survey in the languages offered (n=12); or some other reason rendering them ineligible (n=14). Because our focus was self-reported length of recovery and symptoms, we also excluded asymptomatic cases (n=6), consistent with prior studies [12], and proxy reports due to cognitive ability or incapacitation (n=6). Of the remaining 1909, 629 completed the survey online between June 22 and December 3, 2020, yielding a response rate of 32.9% (American Association for Public Opinion Research (AAPOR) Response Rate #6) and cooperation rate of 56.8% (AAPOR Cooperation Rate #2) [18]. Respondents completed the survey 10-36 weeks post COVID-19 onset (median 17 weeks, IQR 14-20 weeks).

Measures
At the time of the survey respondents answered the following question: “Have you recovered from COVID-19 to your usual state of health?” Respondents who reported they had recovered provided the length of recovery time. Based on length of recovery time for those who had recovered, and time between COVID-19 onset and survey date for those who had not recovered, we calculated the minimum time to recovery for the entire sample. We defined PASC as persistent symptoms 30+ days (30-day COVID-19) or 60+ days (60-day COVID-19) after COVID-19 onset.

Demographic correlates of interest included age group (18-34, 35-44, 45-54, 55-64, 65+), sex (male, female), race/ethnicity (Hispanic, Non-Hispanic (NH) White, NH Black, NH Other), and annual household income (<$35,000, $35,000-$74,999, $75,000+). Clinical correlates included body mass index (BMI, calculated from self-reported height and weight) and the following pre-existing conditions diagnosed prior to the respondent’s COVID-19 diagnosis: asthma, chronic obstructive pulmonary disease (COPD), hypertension, cardiovascular disease, cerebrovascular disease, diabetes, liver disease, kidney disease, cancer, immunosuppressive condition, autoimmune condition, physical disability, or psychological condition. To examine smoking status, we defined current smokers as respondents who had smoked at least 100 lifetime cigarettes and reported smoking every day or some days immediately prior to their illness. Additionally, we assessed the self-reported severity of symptoms when they were at their worst (mild, moderate, severe, or very severe), and hospitalization or intensive care unit (ICU) stay for COVID-19.

Analysis
We produced weighted prevalence estimates of PASC overall and by demographic and clinical correlates. We then used modified Poisson regression to examine unadjusted and adjusted prevalence ratios for demographic and clinical correlates of PASC. Additionally, because hospitalization and ICU stay may lead to prolonged recovery regardless of admitting diagnoses [19, 20], we conducted a sensitivity analysis among non-hospitalized cases in our sample (n=410).

We also produced weighted prevalence estimates of the most common specific ongoing symptoms reported by a subset of 60-day COVID-19 cases (77%) who answered ‘no’ to the question: “Have you recovered from COVID-19 to your usual state of health?” Due to a survey skip pattern, only respondents who had not yet recovered were asked to report the symptoms they were still experiencing at the time of the survey. Since all respondents were at least 60 days post COVID-19 onset at the time of the survey, everyone who reported their specific ongoing symptoms met the criteria for 60-day COVID-19. However, we did not
capture specific ongoing symptoms for 30-day or 60-day COVID-19 cases who had recovered by the time they completed the survey.

Missing data were minimal for each covariate (≤ 1.8%), apart from annual household income (11.0%) and PASC (3.9%). PASC information was available for all respondents who were symptomatic at the time of survey completion (i.e., time elapsed between COVID onset date from MDSS and survey date). We excluded respondents who had recovered by the time of survey completion and did not report a usable length of recovery time (e.g., incomplete, missing, or implausible value) from the analysis. We used multiple imputation to impute missing values for all remaining variables, resulting in an analytic sample size of 593. We controlled for survey mode (32.7% online and 67.3% telephone), sex, age group, race/ethnicity, income, smoking status, BMI, pre-existing comorbidities, self-reported symptom severity, hospitalization, and ICU stay in adjusted analyses. All analyses accounted for the complex sampling design using Stata 15 [21]. We set the statistical significance level at p < 0.05 using a 2-sided test.

Results
Table 1 presents weighted descriptive statistics for the analytic sample. The majority of respondents were female (56.1%), aged 45 or older (68.2%), and Non-Hispanic (NH) White (46.3%) or NH Black (34.8%). Over half of respondents were obese (53.4%). The most prevalent comorbidities were hypertension (43.0%), diabetes (24.5%), asthma (17.1%) and cardiovascular disease (12.3%). With regard to illness severity, most respondents reported severe (39.5%) or very severe symptoms (26.8%), with about one-third reporting mild (13.3%) or moderate symptoms (20.4%). Nearly one-third were hospitalized (32.4%) and 10.1% were admitted to the ICU during the course of their illness. Among respondents who had not recovered to their usual state of health by the time of survey completion, all of whom met the criteria for 60-day COVID-19, the most common specific ongoing symptoms were fatigue (52.9%) and shortness of breath (43.9%) (Figure 1).

Both 30-day and 60-day COVID-19 were highly prevalent in our sample of symptomatic cases (52.5% and 35.0%, respectively; Table 2). Although the prevalence tended to increase with increasing age and disease severity, 30-day and 60-day COVID-19 were still notably prevalent among respondents who were 18-34 years old (34.9% and 21.2%), did not require hospitalization (43.7% and 26.9%, respectively), or reported mild symptoms (29.2% and 24.5%, respectively).

In unadjusted analyses, older age was statistically significantly associated with 30-day and 60-day COVID-19 prevalence (Table 3). Respondents aged 55-64 years had 1.71 times higher prevalence of 30-day COVID-19 (Prevalence Ratio [PR] 1.71, 95% CI 1.19-2.47) and 2.14 times higher prevalence of 60-day COVID-19 (PR 2.14, 95% CI 1.27-3.59) relative to 18-34 year-olds. Point estimates for respondents aged 65+ were similar to respondents aged 55-64, though slightly lower. After adjusting for other demographic factors, pre-existing comorbidities, and illness severity, older age (45+ years) was not statistically significantly associated with increased 30-day or 60-day COVID-19. Additionally, although females had a higher prevalence of 30-day and 60-day COVID-19 than males, this difference was not statistically significant.

Hispanic adults had 48% higher prevalence of 30-day COVID-19 (PR 1.48, 95% CI 1.17-1.86) and 67% higher prevalence of 60-day COVID-19 (PR 1.67, 95% CI 1.18-2.36) than NH White adults in unadjusted models. However, there were no statistically significant differences in 30-day or 60-day COVID-19 by race/ethnicity in the adjusted models. Annual household income was a strong and significant predictor of 30-day COVID-19. Even after adjusting for demographic and clinical factors, respondents with an income less than
$75,000 had about 40% higher prevalence of 30-day COVID-19 than respondents with an income at or above $75,000 (<$35,000 aPR 1.40, 95% CI 1.09-1.79; $35,000-$74,999 aPR 1.38, 95% CI 1.09-1.75). Income was not significantly associated with 60-day COVID-19 in fully adjusted models.

While diagnosed COPD, autoimmune condition, and psychological condition were associated with a higher prevalence of 30-day or 60-day COVID-19, only psychological condition remained statistically significant after adjustment. Respondents with (vs. without) a psychological condition had 42% higher prevalence of 60-day COVID-19 (aPR 1.42, 95% CI 1.00-2.00). Additionally, self-reported acute illness severity was strongly associated with both 30-day and 60-day COVID-19. In adjusted models, respondents reporting very severe (vs. mild) symptoms had 2.25 times higher prevalence of 30-day COVID-19 (aPR 2.25, 95% CI 1.46-3.46) and 1.71 times higher prevalence of 60-day COVID-19 (aPR 1.71, 95% CI 1.02-2.88). Hospitalized (vs. non-hospitalized) respondents had 37% higher prevalence of 30-day COVID-19 (aPR 1.37, 95% CI 1.12-1.69) and 40% higher prevalence of 60-day COVID-19 (aPR 1.40, 95% CI 1.02-1.93).

Results from the sensitivity analysis restricting the sample to non-hospitalized respondents were largely consistent with results from the primary analysis for 30-day COVID-19, with one exception (Table 4). Although cardiovascular disease was not associated with 30-day COVID-19 among the entire sample, non-hospitalized respondents with (vs. without) cardiovascular disease had 54% higher prevalence of 30-day COVID-19 (aPR 1.54, 95% CI 1.01-2.34). Results from the 60-day COVID-19 sensitivity analysis differed from the primary analysis in several notable ways. Among non-hospitalized respondents, psychological condition was not associated with higher 60-day COVID-19 prevalence, while diagnosed COPD was. Additionally, although non-hospitalized respondents reporting severe or very severe (vs. mild) symptoms had higher 30-day COVID-19 prevalence, self-reported symptom severity was not associated with 60-day COVID-19 among non-hospitalized respondents.

Discussion
Our study provides prevalence estimates and correlates of PASC using a probability sample of adults who tested positive in Michigan on or before April 15, 2020. Among symptomatic individuals, persistent symptoms were common: 52.5% had not recovered 30 days post COVID-19 onset (30-day COVID-19) and 35.0% had not recovered 60 days post onset (60-day COVID-19). In fully adjusted models, age (35-44 vs. 18-34 only), low income, self-reported severe or very severe (vs. mild) symptoms, and hospitalization statistically significantly predicted 30-day COVID-19, while having a diagnosed psychological disorder, very severe symptoms, and hospitalization statistically significantly predicted 60-day COVID-19.

In the existing literature, we are only aware of one other probability sample among all diagnosed COVID-19 cases in a geographically defined population examining PASC [13], with the remaining studies limited to hospitalized [3, 4, 7-9], outpatient [2, 10, 12], or other non-probability samples [5, 6, 11]. The population-based study, conducted in the Faroe Islands among a predominantly non-hospitalized sample, reported 53.1% with at least one symptom an average of 125 days post symptom onset [13]. While this estimate is nearly identical to our finding of 30-day COVID-19 prevalence (52.5%), it is higher than our estimate of 60-day COVID-19 (35.0%), possibly due to differences in the populations studied.

Although 30-day and 60-day COVID-19 were more prevalent among individuals with severe illness in our study, they were still highly prevalent among individuals with self-reported mild
to moderate illness. Our finding that 43.7% of non-hospitalized respondents had symptoms 30 days post COVID-19 onset is greater than, but comparable to, a recent study among 14 U.S. academic health systems reporting that 35% of symptomatic outpatient cases had persistent symptoms 14-21 days post SARS-CoV-2 test [12]. These results add to the growing body of evidence that a sizable proportion of symptomatic COVID-19 cases of varying severity experience PASC.

Consistent with recent studies [11-13], older age was associated with persistent COVID-19 symptoms. This finding was no longer statistically significant in adjusted models, suggesting the association with age was due to a higher prevalence of comorbidities and severe illness among older age groups. While Hispanic adults had a higher 30- and 60-day COVID-19 prevalence than NH White adults, this relationship was attenuated after adjusting for demographic and clinical factors. We found no statistically significant difference between NH Black and NH White adults in 30- or 60-day COVID-19 prevalence, supporting the growing body of evidence that Black/White inequities in COVID-19 outcomes are primarily driven by increased risk of exposure for Black individuals, rather than differences in disease severity among those infected [22-24].

Apart from psychiatric conditions, comorbidities did not statistically significantly predict 30- or 60-day COVID-19, suggesting another mechanism underlies the risk of prolonged illness. Moreover, individuals with lower household income (<$75,000) had about 40% higher prevalence of 30-day COVID-19 in fully adjusted models. One potential hypothesis is that greater illness severity, determined by viral dose [25], increases the risk of PASC. This pathway could explain the link between low income and post-acute illness, given that low income individuals may be exposed to a greater viral dose due to inability to work from home [26, 27], lack of adequate personal protective equipment [28], and overcrowded living conditions [26].

There is increasing evidence that illness severity, measured by number of symptoms during the acute phase [5, 11, 13], clinical severity score [9], or hospitalization [11], may increase the risk of PASC. We found that individuals who reported very severe symptoms (vs. mild) were more than twice as likely to have 30-day COVID-19 and 1.71 times as likely to have 60-day COVID-19. Additionally, individuals requiring hospitalization were about 40% more likely to have 30- or 60-day COVID-19 than non-hospitalized individuals in our study. Severe illness may trigger a hyper-inflammatory immune response [25, 29], leading to a prolonged recovery period [30]. Future research is needed to better understand explanatory pathways between illness severity and PASC, including the potential role of viral dose and immune response.

Our study has several limitations. Due to a skip pattern, we did not collect details on specific ongoing symptoms for respondents who reported recovery, including those who met the criteria for 30- or 60-day COVID-19, but were no longer symptomatic at the time of the survey. Additionally, our measure of symptom severity is a subjective measure based on self-report and should be interpreted as such. More broadly, our sample includes individuals with COVID-19 onset in Michigan early in the pandemic when access to testing was limited, which may limit generalizability and bias our results in two ways. First, if severe cases are overrepresented in our sample due to testing prioritization early in the pandemic, we may be overestimating the prevalence of PASC. Second, given the disproportionate lack of testing access for minority and low-income communities [31, 32], our sample may underestimate sociodemographic disparities in PASC. Additionally, our data may be subject to both recall and response bias. Because respondents completed interviews between 10-36 weeks post COVID-19 onset, recall bias may be greater for respondents with a longer period between onset and survey completion. Furthermore, individuals with more severe disease or prolonged symptoms may be more likely to participate. Nevertheless, since the sampling
frame includes all Michigan residents who tested positive, and symptoms among respondents ranged from mild to very severe, our sample is more comprehensive than previous studies.

**Conclusion**
PASC, defined as persistent symptoms 30- or 60-days post onset, is highly prevalent among cases reporting severe initial symptoms, and, to a lesser extent, cases reporting mild or moderate symptoms. Formal, coordinated surveillance of PASC is needed to better understand the disease and provide guidance for clinical management. Although we are still attempting to control COVID-19 spread and treat acute illness, we cannot postpone developing robust efforts to characterize and treat PASC, which may potentially affect millions of COVID-19 survivors worldwide.
NOTES

Acknowledgements
We would like to thank the Michigan COVID-19 Recovery Surveillance Study participants and interviewers for making this study possible. We would also like to acknowledge Yanmei Xie for her assistance with multiple imputation.

Funding
This work was supported by The Michigan Department of Health and Human Services; The Michigan Public Health Institute; The University of Michigan Institute for Data Science; The University of Michigan Rogel Cancer Center; and the University of Michigan Epidemiology Department.

Conflicts of Interest
P.M. reports travel support from the American Veterinary Medical Association, outside the submitted work. All other authors have no conflicts of interest to declare.
References

1. Centers for Disease Control and Prevention. COVIDView: A Weekly Surveillance Summary of U.S. COVID-19 Activity. Available at: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html. Accessed February 6, 2021.
2. Blair PW, Brown DM, Jang M, et al. The clinical course of COVID-19 in the outpatient setting: A prospective cohort study. Open Forum Infectious Diseases 2021.
3. Carfì A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. JAMA 2021; 324(6): 603-5.
4. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. Annals of Internal Medicine 2020.
5. Cirulli ET, Barrett KMS, Riffle S, et al. Long-term COVID-19 symptoms in a large unselected population. MedRxiv (preprint) 2020.
6. Davis HE, Assaf GS, McCorkell L, et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. MedRxiv (preprint) 2020.
7. Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. Journal of Infection 2020; 81(6): e4-e6.
8. Halpin S, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. Journal of medical virology 2021; 93(2).
9. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. The Lancet 2021; 397(10270): 220-32.
10. Nehme M, Braillard O, Alcoba G, et al. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. Annals of Internal Medicine 2020.
11. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. MedRxiv (preprint).
12. Tenforde M, Kim S, Lindsell C, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morbidity and mortality weekly report 2020; 69(30).
13. Petersen MS, Kristiansen MF, Hanusson KD, et al. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients. Clinical Infectious Diseases 2021.
14. Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering Available at: https://coronavirus.jhu.edu/map.html. Accessed February 6, 2020.
15. Alwan N. Surveillance is underestimating the burden of the COVID-19 pandemic. The Lancet 2020; 396.
16. Michigan Department of Health and Human Services. MDHHS Bureau of EMS, Trauma, and Preparedness. Available at: https://www.michigan.gov/mdhhs/0,5885,7-339-71548_54783_54826_56171-237197--,00.html. Accessed February 6, 2020.
17. Deville J, Särndal C. Calibration estimators in survey sampling. Journal of the American statistical Association 1992; 87(418): 376-82.
18. American Association for Public Opinion Research. Standard definitions: Final dispositions of case codes and outcome rates for surveys, 2016.
19. Krumholz HM. Post-hospital syndrome—an acquired, transient condition of generalized risk. N Engl J Med 2013; 368(2): 100-2.
20. Marra A, Pandharipande PP, Girard TD, et al. Co-Occurrence of Post-Intensive Care Syndrome Problems Among 406 Survivors of Critical Illness. Crit Care Med 2018; 46(9): 1393-401.
21. StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC, 2017.
22. Ogedegbe G, Ravenell J, Adhikari S, et al. Assessment of Racial/Ethnic Disparities in Hospitalization and Mortality in Patients With COVID-19 in New York City. JAMA Network Open 2020; 3(12): e2026881.

23. Rentsch CT, Kidwai-Khan F, Tate JP, et al. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLoS Med 2020; 17(9): e1003379.

24. Zelner J, Trangucci R, Naraharisetti R, et al. Racial disparities in COVID-19 mortality are driven by unequal infection risks. Clinical Infectious Diseases 2020.

25. Van Damme W, Dahake R, van de Pas R, Vanham G, Assefa Y. COVID-19: Does the infectious inoculum dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics? Med Hypotheses 2021; 146: 110431.

26. Patel JA, Nielsen FBH, Badiani AA, et al. Poverty, inequality and COVID-19: the forgotten vulnerable. Public Health 2020; 183: 110-1.

27. U.S. Bureau of Labor Statistics. Economic news release: Table 7. Employed persons working on main job at home, workplace, and time spent working at each location by class of worker, occupation, and earnings, 2019 annual averages. Available at: https://www.bls.gov/news.release/atus.t07.htm. Accessed February 8, 2021.

28. McClure ES, Vasudevan P, Bailey Z, Patel S, Robinson WR. Racial Capitalism Within Public Health-How Occupational Settings Drive COVID-19 Disparities. Am J Epidemiol 2020; 189(11): 1244-53.

29. Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or foe? Life Sci 2020; 256: 117900.

30. Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: An Overview and Approach to Classification. Open Forum Infectious Diseases 2021; 7(12).

31. Lieberman-Cribbin W, Tuminello S, Flores RM, Taioli E. Disparities in COVID-19 Testing and Positivity in New York City. Am J Prev Med 2020; 59(3): 326-32.

32. Servick K. 'Huge hole' in COVID-19 testing data makes it harder to study racial disparities. Science. July 10, 2020.
| Table 1. Description of analytic sample (n=593), Michigan COVID-19 Recovery Surveillance Study |
|-------------------------------------------------|-----------------|
| **Sex**                                         | **Weighted Percent** |
| Male                                            | 43.9%            |
| Female                                          | 56.1%            |
| **Mean age (SD)**                               | 51.5 (15.8)      |
| **Age group**                                   |                  |
| 18-34                                           | 15.1%            |
| 35-44                                           | 16.7%            |
| 45-54                                           | 23.6%            |
| 55-64                                           | 25.1%            |
| 65+                                             | 19.6%            |
| **Race/ethnicity**                              |                  |
| Hispanic                                        | 6.0%             |
| Non-Hispanic White                              | 46.3%            |
| Non-Hispanic Black                              | 34.8%            |
| Non-Hispanic Other                              | 12.9%            |
| **Annual household income**                    |                  |
| <$35,000                                        | 31.6%            |
| $35,000 - $74,999                               | 26.8%            |
| $75,000                                         | 41.6%            |
| **Current smoker prior to illness**             | 6.3%             |
| **Body Mass Index**                             |                  |
| Underweight/normal weight (BMI < 25)            | 15.0%            |
| Overweight (BMI 25 to < 30)                     | 31.6%            |
| Obese (BMI 30+)                                 | 53.4%            |
| **Comorbidities**                               |                  |
| Hypertension                                    | 43.0%            |
| Diabetes                                        | 24.5%            |
| Asthma                                          | 17.1%            |
| Cardiovascular disease                          | 12.3%            |
| Psychological condition                         | 9.2%             |
| Physical disability                             | 8.7%             |
| Cancer                                          | 8.6%             |
| Kidney disease                                  | 7.1%             |
| Autoimmune condition                            | 6.5%             |
| Chronic obstructive pulmonary disease           | 5.6%             |
| Cerebrovascular disease                         | 3.8%             |
| Immunosuppressive condition                     | 3.0%             |
| Liver disease                                   | 2.3%             |
Severity of COVID-19 illness

| Self-reported symptom severity | Percentage |
|-------------------------------|------------|
| Mild                          | 13.3%      |
| Moderate                      | 20.4%      |
| Severe                        | 39.5%      |
| Very severe                   | 26.8%      |
| Hospitalized                  | 32.4%      |
| Admitted to Intensive Care Unit| 10.1%      |
|                                | 30-Day COVID-19* | 60-Day COVID-19* |
|--------------------------------|------------------|------------------|
|                                | weighted row percent | 95% CI          | weighted row percent | 95% CI          |
|                                | LB    | UB    | LB    | UB    |
| Total sample                   | 52.5% | 47.8% | 57.2% | 35.0% | 30.5% | 39.5% |
| Sex                            |       |       |       |       |       |       |
| Male                           | 47.4% | 39.9% | 55.0% | 30.9% | 23.8% | 38.0% |
| Female                         | 56.5% | 50.6% | 62.4% | 38.2% | 32.5% | 43.9% |
| Age group                      |       |       |       |       |       |       |
| 18-34                          | 34.9% | 23.3% | 46.5% | 21.2% | 11.2% | 31.3% |
| 35-44                          | 53.0% | 41.3% | 64.7% | 31.8% | 20.9% | 42.7% |
| 45-54                          | 52.1% | 42.4% | 61.8% | 30.1% | 21.2% | 39.0% |
| 55-64                          | 59.8% | 50.6% | 69.0% | 45.4% | 36.1% | 54.7% |
| 65+                            | 56.8% | 46.5% | 67.1% | 41.0% | 30.8% | 51.1% |
| Race/ethnicity                 |       |       |       |       |       |       |
| Hispanic                       | 72.9% | 58.8% | 86.9% | 56.3% | 39.6% | 72.9% |
| Non-Hispanic White             | 49.4% | 42.9% | 55.9% | 33.7% | 27.6% | 39.9% |
| Non-Hispanic Black             | 54.2% | 45.7% | 62.7% | 36.4% | 28.2% | 44.7% |
| Non-Hispanic Other             | 49.7% | 35.8% | 63.5% | 25.9% | 13.7% | 38.0% |
| Annual household income        |       |       |       |       |       |       |
| <$35,000                       | 61.0% | 52.4% | 69.6% | 42.7% | 34.1% | 51.4% |
| $35,000 - $74,999              | 60.7% | 51.7% | 69.7% | 38.6% | 29.6% | 47.6% |
| $75,000                        | 40.8% | 33.5% | 48.1% | 26.8% | 20.2% | 33.4% |
| Smoking status prior to illness|       |       |       |       |       |       |
| Non-smoker                     | 52.5% | 47.7% | 57.3% | 35.0% | 30.5% | 39.6% |
| Smoker                         | 52.2% | 33.0% | 71.5% | 34.2% | 16.1% | 52.3% |
| Body Mass Index                |       |       |       |       |       |       |
| Underweight/normal weight (BMI < 25) | 44.1% | 32.6% | 55.5% | 30.8% | 20.1% | 41.5% |
| Overweight (BMI 25 to < 30)    | 49.8% | 41.4% | 58.2% | 32.0% | 24.1% | 40.0% |
| Obese (BMI 30+)                | 56.5% | 50.1% | 62.9% | 37.9% | 31.7% | 44.2% |

Comorbidities
| Condition                  | No  | Yes  |
|----------------------------|-----|------|
| Hypertension               | 48.8% | 57.4% |
| Diabetes                   | 50.3% | 59.2% |
| Asthma                     | 52.3% | 53.4% |
| Cardiovascular disease     | 52.4% | 53.4% |
| Psychological condition    | 50.8% | 53.4% |
| Physical disability        | 51.7% | 69.6% |
| Cancer                     | 52.6% | 60.8% |
| Kidney disease             | 52.8% | 52.0% |
| Autoimmune condition       | 51.6% | 49.1% |
| COPD                       | 51.2% | 74.2% |
| Cerebrovascular disease    | 52.3% | 35.0% |
|                                | No   | Yes  | No   | Yes  | No   | Yes  |
|--------------------------------|------|------|------|------|------|------|
| Immunosuppressive condition    |      |      |      |      |      |      |
| No                             | 52.0%| 70.7%| 47.2%| 44.6%| 56.7%| 96.7%|
| Yes                            | 56.9%| 32.3%| 81.5%| 34.3%| 34.4%| 29.9%|
| Liver disease                  |      |      |      |      |      |      |
| No                             | 52.5%| 54.4%| 47.8%| 15.0%| 57.2%| 93.9%|
| Yes                            | 70.7%| 70.7%| 61.8%| 61.8%| 96.7%| 96.7%|
| Severity of COVID-19 illness   |      |      |      |      |      |      |
| Self-reported symptom severity |      |      |      |      |      |      |
| Mild                           | 29.2%| 33.7%| 17.3%| 24.5%| 41.2%| 42.9%|
| Moderate                       | 33.7%| 33.7%| 24.5%| 24.5%| 42.9%| 42.9%|
| Severe                         | 54.2%| 75.8%| 46.6%| 68.1%| 61.9%| 83.6%|
| Very severe                    | 75.8%| 75.8%| 68.1%| 68.1%| 83.6%| 83.6%|
| Hospitalized                   |      |      |      |      |      |      |
| No                             | 43.7%| 43.7%| 38.1%| 63.2%| 49.3%| 78.6%|
| Yes                            | 70.9%| 70.9%| 63.2%| 63.2%| 78.6%| 78.6%|
| Admitted to Intensive Care Unit|      |      |      |      |      |      |
| No                             | 50.0%| 50.0%| 45.0%| 45.0%| 54.9%| 54.9%|
| Yes                            | 75.1%| 75.1%| 61.6%| 61.6%| 88.7%| 88.7%|

*Defined as persistent symptoms at least 30 days (30-day COVID-19) or 60 days (60-day COVID-19) post COVID-19 onset

LB = lower bound; UB = upper bound; COPD = Chronic obstructive pulmonary disease

† Negative lower bound due to small sample size replaced by 0
Table 3. Predictors of post-acute sequelae of SARS-CoV-2 infection using modified Poisson regression (n=593), Michigan COVID-19 Recovery Surveillance Study

|                        | 30-Day COVID-19\(^{+}\) |           | 60-Day COVID-19\(^{+}\) |           |
|------------------------|--------------------------|-----------|--------------------------|-----------|
|                        | Unadjusted               | Adjusted\(^\wedge\) | Unadjusted               | Adjusted\(^\wedge\) |
|                        | PR 95% CI                 | PR 95% CI  | PR 95% CI                 | PR 95% CI  |
| **Sex**                |                          |           |                          |           |
| Male                   | 1.00                     | 1.00      | 1.00                     | 1.00      |
| Female                 | 1.19 [0.98, 1.44]         | 1.16 [0.97, 1.40] | 1.24 [0.94, 1.63] | 1.19 [0.91, 1.55] |
| **Age group**          |                          |           |                          |           |
| 18-34                  | 1.00                     | 1.00      | 1.00                     | 1.00      |
| 35-44                  | 1.52* [1.02, 2.26]        | 1.48* [1.02, 2.14] | 1.50 [0.83, 2.68] | 1.42 [0.83, 2.43] |
| 45-54                  | 1.49* [1.19, 2.19]        | 1.41 [0.95, 2.04] | 1.42 [1.27, 2.48] | 1.33 [0.78, 2.27] |
| 55-64                  | 1.71** [1.12, 2.47]       | 1.37 [0.93, 1.99] | 2.14** [1.13, 3.59] | 1.61 [0.88, 2.68] |
| 65+                    | 1.63* [1.12, 2.38]        | 1.34 [0.93, 1.94] | 1.93* [1.13, 3.29] | 1.52 [0.88, 2.62] |
| **Race/ethnicity**     |                          |           |                          |           |
| Hispanic               | 1.48** [1.17, 1.86]       | 1.14 [0.87, 1.49] | 1.67** [1.18, 2.36] | 1.28 [0.89, 1.83] |
| Non-Hispanic White     | 1.00 [0.89, 1.35]         | 1.14 [0.74, 1.14] | 1.08 [0.68, 1.44] | 0.93 [0.46, 1.27] |
| Non-Hispanic Black     | 1.10 [0.74, 1.37]         | 0.92 [0.73, 1.29] | 0.77 [0.46, 1.27] | 0.78 [0.46, 1.31] |
| Non-Hispanic Other     | 1.01 [1.01, 1.37]         | 0.97 [1.01, 1.29] | 0.77 [1.01, 1.27] | 0.78 [1.01, 1.31] |
| **Annual household income** |                    |           |                          |           |
| <$35,000               | 1.50*** [1.18, 1.89]      | 1.40** [1.09, 1.79] | 1.59** [1.15, 2.20] | 1.31 [0.93, 1.85] |
| $35,000 - $74,999      | 1.49*** [1.18, 1.87]      | 1.38** [1.09, 1.75] | 1.44* [1.03, 2.02] | 1.27 [0.90, 1.78] |
| $75,000                | 1.00 [1.00, 1.00]         | 1.00 [1.00, 1.00] | 1.00 [1.00, 1.00] | 1.00 [1.00, 1.00] |
| Current smoker prior to illness | 0.99 | [0.68, 1.45] | 1.18 | [0.82, 1.71] | 0.98 | [0.57, 1.68] | 1.11 | [0.63, 1.95] |
|-------------------------------|------|--------------|------|--------------|------|--------------|------|--------------|
| BMI                          |      |              |      |              |      |              |      |              |
| underweight/normal weight    | 1.00 | 1.00         |      |              | 1.00 |              |      |              |
| overweight                   | 1.13 | [0.83, 1.55] | 0.98 | [0.74, 1.29] | 1.04 | [0.68, 1.60] | 0.89 | [0.60, 1.32] |
| obese                        | 1.28 | [0.96, 1.73] | 0.96 | [0.73, 1.25] | 1.23 | [0.84, 1.81] | 0.93 | [0.63, 1.36] |
| Comorbidities                |      |              |      |              |      |              |      |              |
| Hypertension                 | 1.17 | [0.98, 1.40] | 1.02 | [0.84, 1.24] | 1.19 | [0.93, 1.54] | 1.00 | [0.76, 1.31] |
| Diabetes                     | 1.18 | [0.97, 1.43] | 1.07 | [0.87, 1.32] | 1.24 | [0.94, 1.64] | 1.03 | [0.71, 1.37] |
| Asthma                       | 1.02 | [0.77, 1.28] | 0.92 | [0.72, 1.14] | 1.09 | [0.82, 1.50] | 0.96 | [0.70, 1.30] |
| Cardiovascular disease       | 1.02 | [1.10, 1.34] | 0.96 | [0.95, 1.28] | 1.17 | [1.20, 1.68] | 1.05 | [1.00, 1.57] |
| Psychological condition      | 1.37** | [0.89, 1.70] | 1.22 | [0.64, 1.59] | 1.64** | [0.87, 2.23] | 1.42* | [1.00, 2.00] |
| Physical disability          | 1.17 | [0.73, 1.56] | 0.87 | [0.74, 1.18] | 1.29 | [0.57, 1.89] | 0.82 | [0.48, 1.24] |
| Cancer                       | 0.99 | [0.62, 1.33] | 0.97 | [0.49, 1.26] | 0.88 | [0.66, 1.38] | 0.74 | [0.51, 1.14] |
| Kidney disease               | 0.93 | [0.96, 1.39] | 0.72 | [0.85, 1.06] | 1.09 | [1.17, 1.81] | 0.85 | [0.98, 1.40] |
| Autoimmune condition         | 1.26 | [1.15, 1.66] | 1.13 | [0.80, 1.51] | 1.65** | [1.51, 2.32] | 1.46 | [1.06, 2.17] |
| COPD                         | 1.45** | [0.70, 1.83] | 1.07 | [0.65, 1.42] | 2.02*** | [1.51, 2.71] | 1.40 | [0.96, 2.02] |
| Cerebrovascular disease      | 1.09 | [0.92, 1.69] | 0.97 | [0.76, 1.46] | 0.98 | [0.49, 1.94] | 0.76 | [0.41, 1.41] |
| Immunosuppressive condition  | 1.36 | [1.99, 1.16] | 1.16 | [0.76, 1.78] | 1.53 | [0.91, 2.59] | 1.12 | [0.61, 2.07] |
| Liver disease                | 1.02 | [0.49, 0.91] | 0.91 | [0.44, 0.82] | 0.82 | [0.26, 0.66] | 0.66 | [0.26, 1.02] |
| Severity of COVID-19 illness | Self-reported symptom severity | Mild | [0.70, 1.00] | [0.78, 1.00] | [0.39, 1.00] | [0.42, 1.00] |
|-----------------------------|--------------------------------|------|---------------|---------------|---------------|---------------|
|                             | Moderate                       | 1.15 | [1.20, 1.70]  | [1.25, 2.00]  | [0.83, 1.31]  | [0.81, 1.42]  |
|                             | Severe                         | 1.86** | 2.86[1.70]   | 1.91**[1.46]  | 1.40[1.36]    | 0.71[0.42]    |
|                             | Very severe                    | 2.59*** | 3.95[1.37]   | 2.25***[1.12] | 2.24**[1.51]  | 1.71*[1.02]   |
|                             | Hospitalized                   | 1.62*** | 1.92[1.22]   | 1.37**[0.75]  | 1.92***[1.61] | 1.40*[0.84]   |
|                             | Admitted to Intensive Care Unit| 1.50*** | 1.85[1.22]   | 0.94[0.75]    | 2.09***[1.61] | 1.16[1.02]    |

+Defined as persistent symptoms at least 30 days (30-day COVID-19) or 60 days (60-day COVID-19) post COVID-19 onset
^Mutually adjusted for all covariates and survey mode
* p<0.05, ** p<0.01, *** p<0.001

PR = prevalence ratio; COPD = Chronic obstructive pulmonary disease
Table 4. Predictors of post-acute sequelae of SARS-CoV-2 infection among respondents who did not require hospitalization for COVID-19 using modified Poisson regression (n=410), Michigan COVID-19 Recovery Surveillance Study

|                          | 30-Day COVID-19* | 60-Day COVID-19* |
|--------------------------|------------------|------------------|
|                          | Adjusted PR\(^a\) | 95% CI           | Adjusted PR\(^a\) | 95% CI           |
| Sex                      |                  |                  |                  |                  |
| Male                     | 1.00             |                  | 1.00             |                  |
| Female                   | 1.29 [0.97, 1.71]| 1.48 [0.97, 2.26]|                  |                  |
| Age group                |                  |                  |                  |                  |
| 18-34                    | 1.00             |                  | 1.00             |                  |
| 35-44                    | 1.55* [1.02, 2.34]| 1.45 [0.75, 2.78]|                  |                  |
| 45-54                    | 1.21 [0.79, 1.85]| 1.02 [0.55, 1.92]|                  |                  |
| 55-64                    | 1.26 [0.82, 1.94]| 1.60 [0.90, 2.86]|                  |                  |
| 65+                      | 1.24 [0.76, 2.04]| 1.72 [0.84, 3.54]|                  |                  |
| Race/ethnicity           |                  |                  |                  |                  |
| Hispanic                 | 1.15 [0.77, 1.73]| 1.01 [0.55, 1.84]|                  |                  |
| Non-Hispanic White       | 1.00             |                  | 1.00             |                  |
| Non-Hispanic Black       | 0.93 [0.65, 1.34]| 0.73 [0.44, 1.21]|                  |                  |
| Non-Hispanic Other       | 1.00 [0.68, 1.48]| 0.82 [0.43, 1.57]|                  |                  |
| Annual household income  |                  |                  |                  |                  |
| <$35,000                 | 1.45* [1.00, 2.08]| 1.43 [0.85, 2.41]|                  |                  |
| $35,000 - $74,999        | 1.56** [1.13, 2.15]| 1.38 [0.87, 2.18]|                  |                  |
| $75,000                  | 1.00             |                  | 1.00             |                  |
| Current smoker prior to illness | 1.28 [0.76, 2.16]| 1.45 [0.67, 3.11]|                  |                  |
| BMI                      |                  |                  |                  |                  |
| underweight/normal weight| 1.00             |                  | 1.00             |                  |
| overweight               | 0.94 [0.65, 1.36]| 0.85 [0.50, 1.46]|                  |                  |
| obese                    | 0.95 [0.65, 1.38]| 0.92 [0.53, 1.59]|                  |                  |
| Comorbidities            |                  |                  |                  |                  |
| Hypertension             | 0.95 [0.70, 1.30]| 0.92 [0.58, 1.47]|                  |                  |
| Diabetes                 | 0.97 [0.68, 1.39]| 1.15 [0.72, 1.83]|                  |                  |
| Asthma                   | 0.92 [0.66, 1.27]| 0.99 [0.61, 1.62]|                  |                  |
| Condition                        | Prevalence Ratio | 95% CI       | Odds Ratio | 95% CI       |
|---------------------------------|------------------|--------------|------------|--------------|
| Cardiovascular disease          | 1.54*            | [1.01, 2.34] | 1.82       | [0.95, 3.49] |
| Psychological condition         | 1.32             | [0.94, 1.83] | 1.40       | [0.83, 2.36] |
| Physical disability             | 0.82             | [0.47, 1.44] | 0.72       | [0.37, 1.43] |
| Cancer                          | 0.68             | [0.41, 1.14] | 0.49       | [0.24, 1.02] |
| Kidney disease                  | 0.92             | [0.50, 1.69] | 1.05       | [0.44, 2.51] |
| Autoimmune condition            | 1.22             | [0.79, 1.89] | 1.38       | [0.75, 2.54] |
| COPD                            | 1.38             | [0.91, 2.08] | 1.80*      | [1.02, 3.19] |
| Cerebrovascular disease         | 1.04             | [0.48, 2.26] | 0.40       | [0.12, 1.36] |
| Immunosuppressive condition     | 1.23             | [0.57, 2.65] | 1.85       | [0.76, 4.47] |
| Liver disease                   | 0.46             | [0.10, 2.08] | 0.27       | [0.03, 2.54] |
| **Severity of COVID-19 illness** |                  |              |            |              |
| **Self-reported symptom severity** |                |              |            |              |
| Mild                            | 1.00             |              | 1.00       |              |
| Moderate                        | 1.25             | [0.69, 2.26] | 0.64       | [0.31, 1.29] |
| Severe                          | 1.85*            | [1.04, 3.30] | 1.09       | [0.58, 2.08] |
| Very severe                     | 2.43**           | [1.33, 4.45] | 1.66       | [0.84, 3.29] |

+Defined as persistent symptoms at least 30 days (30-day COVID-19) or 60 days (60-day COVID-19) post COVID-19 onset

^Mutually adjusted for all covariates with prevalence ratio value and survey mode

* p<0.05, ** p<0.01, *** p<0.001

PR = prevalence ratio; COPD = Chronic obstructive pulmonary disease
Figure 1. Prevalent symptoms among respondents with 60-Day COVID-19+ who had not recovered by the time they were surveyed (n=170)^

+Defined as persistent symptoms at least 60 days post COVID-19 onset
^Respondents who answered 'no' to the question: “Have you recovered from COVID-19 to your usual state of health?”
| Symptom                                      | Percentage |
|----------------------------------------------|------------|
| Fatigue                                      | 52.9       |
| Shortness of breath                          | 43.9       |
| Altered sense of taste or smell              | 19.4       |
| Muscle or joint pain                         | 18.4       |
| Weakness (general or in extremities)         | 16.4       |
| Cough                                        | 15.9       |
| Headache                                     | 9.9        |
| Chest pain / tightness                       | 9.9        |
| Hair loss                                    | 9.8        |
| Cognitive dysfunction                        | 9.1        |
| Nasal congestion                             | 7.9        |
| Difficulty sleeping                          | 6.0        |
| Dizziness                                    | 5.6        |
| Gastrointestinal issues                      | 5.4        |